These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11080321)

  • 1. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.
    Boriani G; Biffi M; Frabetti L; Maraschi M; Branzi A
    Heart Lung; 2000; 29(6):412-6. PubMed ID: 11080321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
    Dorian P; Newman D; Harris L; Downar E
    Can J Cardiol; 1994 Mar; 10(2):193-200. PubMed ID: 8143220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation.
    Leong-Sit P; Gula LJ; Diamantouros P; Krahn AD; Skanes AC; Yee R; Klein GJ
    Am Heart J; 2006 Dec; 152(6):1104-8. PubMed ID: 17161062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy.
    Dorian P; Newman D; Sheahan R; Tang A; Green M; Mitchell J
    J Cardiovasc Electrophysiol; 1996 Oct; 7(10):952-61. PubMed ID: 8894937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Implantation of a transvenous defibrillation system in isolated persistent left superior vena cava].
    Peters W; Krein A; Kowallik P; Wittenberg G; Meesmann M
    Dtsch Med Wochenschr; 1997 Mar; 122(12):366-70. PubMed ID: 9118791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of antiarrhythmic drugs in reducing the number of defibrillation shocks].
    Deharo JC; Mouliom F; Salamand A; Djiane P
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):140-4. PubMed ID: 15787306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone.
    Tsagalou EP; Kanakakis J; Rokas S; Anastasiou-Nana MI
    Int J Cardiol; 2005 Mar; 99(2):341-2. PubMed ID: 15749200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators.
    Kruger A; Aronow WS; Lai H; Desai H; Singla A; Frishman WH; Cohen M; Sorbera C
    Am J Ther; 2009; 16(4):323-5. PubMed ID: 19617719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy.
    Cawley PJ; Al-Khatib SM
    Am Heart J; 2004 May; 147(5):790-1. PubMed ID: 15131532
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-determinable defibrillation threshold and inefficacy of implantable cardioverter/defibrillator shocks due to defective connections of the defibrillator lead terminals in the device header port.
    Maagh P; Trappe HJ; Meissner A
    Europace; 2007 Dec; 9(12):1161-2. PubMed ID: 17913694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects.
    Piccirillo G; Magrì D; Matera S; Magnanti M; Pasquazzi E; Schifano E; Velitti S; Mitra M; Marigliano V; Paroli M; Ghiselli A
    Transl Res; 2008 May; 151(5):267-72. PubMed ID: 18433709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Massive myocardial hypertrophy in hypertrophic cardiomyopathy: a risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation].
    Jastrzebski M; Czarnecka D; Bacior B; Petkow-Dimitrow P; Wilczek R; Kawecka-Jaszcz K
    Kardiol Pol; 2005 Aug; 63(2):191-5; discussion 196. PubMed ID: 16136416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.